The FDA approved deucravacitinib (Sotyktu, Bristol Myers Squibb), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib is not recommended for use in combination with other potent immunosuppressants.
The approval is based on results from the pivotal phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials, which demonstrated